Phase I for Acorda's new mechanism of action in heart failure justifies more studies
This article was originally published in Scrip
Phase I data are sufficient to justify another human clinical trial in the treatment of heart failure with Acorda Therapeutics' glial growth factor 2 (GGF2), which offers a new mechanism of action that may improve heart function through direct repair of cardiac muscle.
You may also be interested in...
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.
Private Company Edition: Venture capital invested in pharma and biotech in 2020 totaled $19.5m through Q3, just $400m below the full-year record total of $19.9bn in 2018. Also, Canaan and Catalio reveal new VC funds, while Talaris’s $115m series B leads recent financings.
Biopharma executives discussed their strategies for treating chronic diseases during the Cell and Gene Meeting on the Mesa, including R&D and regulatory considerations.